(Q37878072)

24 August 2017

title

Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae (English)

1 reference

24 August 2017

Chlamydia pneumoniae

1 reference

Roblin PM

1

1 reference

24 August 2017

Kutlin A

series ordinal

2

1 reference

24 August 2017

Reznik T

series ordinal

3

1 reference

24 August 2017

Hammerschlag MR

series ordinal

4

1 reference

24 August 2017

publication date

1 July 1999

1 reference

International Journal of Antimicrobial Agents

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

181-184

1 reference

A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

In vitro activities of five quinolones against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900057-6

7 January 2021

10.1016/S0924-8579(99)00057-6

Identifiers

DOI

1 reference

24 August 2017

1 reference